Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 163 participants.
Also called NCT02584504
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 163 participants
- Sponsor
- Registry
-
NCT02584504
-
- Other papers using this trial's data
- Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02584504. Randomized; quadruple masking; primary purpose treatment. Start 2015-11-30 (actual); primary completion 2017-04-05 (actual). Results posted on 2018-05-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin
- Acronym
- ODYSSEY-NIPPON
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Alirocumab
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Atorvastatin
- Intervention (Drug)
- Non-statin Lipid-Modifying Therapy
- Intervention (Other)
- Diet Alone
- Lead sponsor
- Sanofi
- Collaborator
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct02584504- Content hash
5fe86e04e987e25055178f7e5cb245f5dce26314f7b82b7ec6c8b4b64a5ff5aa